On the recordJuly 19, 2011
It is not very useful to investors to have the reams of data about Sarbanes-Oxley for a firm that has no revenue yet.
Source
congress.govIt is not very useful to investors to have the reams of data about Sarbanes-Oxley for a firm that has no revenue yet.
Toomey argues that Sarbanes-Oxley data is irrelevant for pre-revenue biotech firms.
Share
More from Pat Toomey
Cryptocurrencies can protect against inflation when Governments irresponsibly manage their own currencies.
I think there is a case to be made that there should be a regulatory regime on disclosure requirements for an issuer.
It is absolutely essential to investigate any fraud and violations of existing law, and prosecute those who are committing those crimes.